Cargando…
Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience
PURPOSE: Taxanes are a cornerstone treatment in early and advanced stage breast cancer and in other common solid tumor malignancies; however, the development of chemotherapy induced peripheral neuropathy (CIPN) often necessitates dose-reduction, which may hamper the effectiveness of the drug and com...
Autores principales: | Bhatnagar, Bhavana, Gilmore, Steven, Goloubeva, Olga, Pelser, Colleen, Medeiros, Michelle, Chumsri, Saranya, Tkaczuk, Katherine, Edelman, Martin, Bao, Ting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117856/ https://www.ncbi.nlm.nih.gov/pubmed/25089251 http://dx.doi.org/10.1186/2193-1801-3-366 |
Ejemplares similares
-
Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
por: Molassiotis, Alex, et al.
Publicado: (2019) -
Chemotherapy-induced peripheral neuropathy
por: Zhang, Xia, et al.
Publicado: (2017) -
Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
por: Melchior, Nicole M., et al.
Publicado: (2020) -
Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease?
por: Zabell, Joseph, et al.
Publicado: (2018) -
Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy
por: Sui, Wilson, et al.
Publicado: (2017)